UniQure has outlined its plans for the AMT-130 Biologics License Application (BLA) this quarter, supported by a cash runway extending into 2030.

An analysis discusses potential future FDA reversals in drug approvals, referencing recent cases involving UniQure and Regenxbio.

Regenxbio and Replimune were among the top gainers in the biotech sector following a U-turn by the FDA regarding UniQure, indicating a positive market response to the regulatory development.

Investors considering Uniqure NV (QURE) stock are advised to review information related to its AMT-130 program.

UniQure announced its intention to submit a Marketing Authorization Application (MAA) for AMT-130 in the U.K. during Q3. The company also projects its cash reserves will extend into the second half of 2029.

Viridian Therapeutics and uniQure N.V. have both reported substantial year-on-year stock growth, with Viridian posting double-digit gains and uniQure N.V. achieving 30% growth. These figures highlight strong performance for the respective companies.

UniQure needs to run another trial to prove its gene therapy "actually helps people with Huntington's disease," said a senior FDA official.

Several companies, including AES, Amazon, American Air, Exxon, and UniQure, are identified as significant movers in the US premarket trading.

An article provides a preview of uniQure's upcoming fourth-quarter 2025 earnings report, outlining expectations for the biotechnology company's financial performance.

MoonLake Immunotherapeutics and uniQure have both announced proposed public offerings of ordinary shares, each aiming to raise $150 million. These offerings are intended to secure significant capital for their respective companies.

Several stocks, including SpaceX, JPMorgan, UniQure, Intel, Figma, and Nano Nuclear, are experiencing significant movements in midday trading.

An analysis evaluates whether uniQure N.V. (QURE) is a good stock investment opportunity at the current time.

Barclays has reaffirmed its 'Equal Weight' rating for uniQure (QURE), maintaining its neutral outlook on the biotechnology company's stock performance.

The deadline for investors to lead a securities fraud lawsuit against uniQure N.V. (QURE) is April 13, 2026, with Kaplan Fox encouraging contact.

FDA official says UniQure fell short on Huntington's trial, defends new study request  Reuters

UniQure N.V. (QURE) has seen its stock upgraded to 'Overweight' by analysts, attributed to the advancement of its Huntington’s Disease program.

UniQure (QURE) shares surged by 78% after the company announced significant progress with its AMT-130 treatment.

UniQure plans to submit a U.S. marketing application to the FDA for its Huntington's disease gene therapy. This move follows a previous disagreement with the agency regarding the treatment.

uniQure has released highlights from its first-quarter earnings call, providing an overview of its financial performance and business developments.

uniQure's stock has seen an increase after the company provided regulatory updates concerning its gene therapy developments.

UniQure slides after FDA says trial data insufficient for brain disorder therapy filing  TradingView

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.